Speakers

Cezmi Akdis

Director of the Swiss Institute of Allergy and Asthma Research (SIAF), Davos

Ordinarius Professor in Zurich University Medical Faculty

Honorary Professor: Beijign, Wuhan and Bursa Universities

Senate Member of Swiss Academy of Medical Sciences

Articles in peer-reviewed journals: 600; editorial articles: 28; total number of citations: 43’673; h-index: 110; Thomson Reuters (Clarivate) highly cited author: 2016-2017-2018-2019-2020-2021.

President of the European Academy of Allergy & Clinical Immunology (14’000 members) between 2011-2013.

Editor: Global Atlas of Allergy, Asthma I-II, Chronic rhinosinusitis and Allergic Rhinitis.

Founder and organizer of World Immune Regulation Meetings, Davos I-XV (600-1000 participants).

Editor-in-Chief: Allergy

Major contributions: Immune regulation and allergen tolerance, plasticity of antigen-specific T cells 1995, human T regulatory cells 1996, immune suppressive role of histamine receptor 2 2000, human Type 2 NK cell subset 2001, human regulatory NK cells 2007, regulatory innate B cell subset 2017, regulatory innate lymphoid cells 2019.

Epithelial barrier hypothesis studies: Mechanisms of eczema 2000, mechanisms of epithelial shedding in asthma and chronic rhinosinusitis 2003, endotypes of asthma, chronic rhinosinusitis and atopic dermatitis 2011, epithelial barrier hypothesis for the development of allergic and autoimmune diseases 2017, 2019. More than 30 publications on COVID-19, pathophysiology, risk factors, severity, patient characteristics and how to handle allergy and asthma patients.

Cezmi Akdis is the director of the Swiss Institute of Allergy and Asthma Research (SIAF) located in Davos and Ordinarius Professor in Zurich University Medical Faculty. He has honorary professorships from Beijign, Wuhan (China) and Bursa Uludag Universities (Turkey). He is a Senate Member of the Swiss Academy of Medical Sciences. 

Cezmi Akdis has published more than 600 peer-reviewed articles. His h-index is 110 and he was selected as a highly cited author consecutively in 2016-2017-2018-2019-2020 and 2021 by Clarivate (Thomson Reuters).

Cezmi Akdis acted as the President of the European Academy of Allergy & Clinical Immunology (15’000 members) between 2011-2013. He was the editor of Global Atlases of Allergy, Asthma I-II, Chronic Rhinosinusitis and Allergic Rhinitis.

He was the founder and organizer of the World Immune Regulation Meetings, Davos I-XV (600-1000 participants). 

He is currently the Editor-in-Chief of Allergy, impact factor 13.15.

Cezmi Akdis’s major scientific contributions are on immune regulation and allergen tolerance, plasticity of antigen-specific T cells 1995, human T regulatory cells 1996, immune suppressive role of histamine receptor 2 2000, human Type 2 NK cell subset 2001, human regulatory NK cells 2007, regulatory innate B cell subset 2017, regulatory innate lymphoid cells 2019. 

His current research is the continuation of his epithelial barrier hypothesis studies starting from mechanisms of eczema 2000, mechanisms of epithelial shedding in asthma and chronic rhinosinusitis 2003, endotypes of asthma, chronic rhinosinusitis and atopic dermatitis 2011, epithelial barrier hypothesis for the development of allergic and autoimmune diseases 2015 - 2022. Cezmi Akdis is an author of more than 40 publications on COVID-19 and SARS-CoV-2 including pathophysiology, risk factors, severity, patient characteristics and how to handle allergy and asthma patients during the pandemic.

 

Back to overview